MMM
35
5
LNC
45
2
MCK
64
-2
SE
50
-2
TXT
68
2
FITB
58
3
EQT
53
-6
CHD
61
-3
KIM
48
-6
NVDA
56
-4
GE
67
-3
SWKS
38
-15
NI
50
2
R
65
2
NTRS
29
2
YUM
57
-9
EBAY
47
-2
CFG
24
4
BLK
57
3
AEP
42
3
MMM
35
5
LNC
45
2
MCK
64
-2
SE
50
-2
TXT
68
2
FITB
58
3
EQT
53
-6
CHD
61
-3
KIM
48
-6
NVDA
56
-4
GE
67
-3
SWKS
38
-15
NI
50
2
R
65
2
NTRS
29
2
YUM
57
-9
EBAY
47
-2
CFG
24
4
BLK
57
3
AEP
42
3
Financhill
Back

Cara Therapeutics 10K Form

Sell
24

CARA
Cara Therapeutics

Last Price:
0.77
Seasonality Move:
2.16%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-13 10Q CARA/Cara Therapeutics Quarterly
2023-08-07 10Q CARA/Cara Therapeutics Quarterly
2023-05-15 10Q CARA/Cara Therapeutics Quarterly
2022-11-07 10Q CARA/Cara Therapeutics Quarterly
2022-08-08 10Q CARA/Cara Therapeutics Quarterly
2022-05-09 10Q CARA/Cara Therapeutics Quarterly

Receive CARA News And Ratings

See the #1 stock for the next 7 days that we like better than CARA

CARA Financial Statistics

Sales & Book Value

Annual Sales: $20.97M
Cash Flow: $-19.42M
Price / Cash Flow: 0
Annual Sales: $1.05
Price / Book: 0.71

Profitability

EPS (TTM): -2.19000
Net Income (TTM): $-118.51M
Gross Margin: $14.79M
Return on Equity: -108.32%
Return on Assets: -83.33%

Cara Therapeutics Earnings Forecast

Key Cara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for CARA is 70.56%.
  • The Selling, General & Administrative Expenses for CARA have been equal to 131.86% of Gross Profit Margin.
  • The Research & Development expenses have been 517.50% of Revenue.
  • The Interest Expense is -0.51% of Operating Income.
  • The Net Earning history of CARA is -565.21% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Cara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CARA
CUSIP: 140755
Website: caratherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.54
Quick Ratio: 4.09

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CARA Technical Analysis vs Fundamental Analysis

Sell
24
Cara Therapeutics (CARA) is a Sell

Is Cara Therapeutics a Buy or a Sell?

  • Cara Therapeutics stock is rated a Sell
    The current Cara Therapeutics [CARA] share price is $0.74. The Score for CARA is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.